 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Pyrazinamide drug susceptibility testing in Mycobacterium tuberculosis |
| Language |
J |
| AuthorList |
Akio Aono |
| Affiliation |
Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association |
| Publication |
J.J.C.M.: 32 (4), 205-210, 2022 |
| Received |
July 29, 2022 |
| Accepted |
|
| Abstract |
The incidence of tuberculosis (TB) in Japan is 10.1 per 100,000 population in 2020, and it remains one of the most important infectious diseases in public health. Chemotherapy for TB is generally a combination of multiple drugs, and pyrazinamide (PZA) plays an important role in the standard of care and in the treatment of multidrug-resistant TB. PZA is a prodrug that is converted to pyrazinoic acid (POA) by pyrazinamidase (PZase), an enzyme possessed by Mycobacterium tuberculosis, and exhibits antibacterial activity. The antimicrobial activity of PZA is strongly influenced by pH and increases in the acidic range of pH 5.0 to 5.5. The pncA is the main gene involved in PZA resistance. In addition, panD, rpsA, and clpC1 have been reported as potential responsible genes. A test that correlates very well with mutations in the pncA gene is the PZase test. We have reported a simple method to measure PZase activity quantitatively using absorbance. We believe that this method can be introduced into clinical practice because of its simplicity and ease of use. Many false resistances have been reported in the PZA drug susceptibility testing. We believe that a combination of genotypic and phenotypic drug susceptibility testing is necessary to more accurately assess PZA resistance. |
| Keywords |
pyrazinamide |
|
